Alpha-GPC for Focus & Concentration
Choline compound that crosses the blood-brain barrier efficiently and is metabolised to free choline, a building block for acetylcholine; studied for cognitive performance and, at higher doses, acute power output in training.
The connection
Difficulty concentrating, brain fog, and attention issues. Increasingly common in the age of distraction.
Also known as: Alpha-glycerylphosphorylcholine
Alpha-GPC × Focus & Concentration: at a glance
Every published result for this pair, extracted and audited.
Alpha-GPC / Focus & Concentration: publication years
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Publications (count) |
|---|---|
| 2014 | 1 |
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Alpha-GPC × Focus & Concentration: the evidence base
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Neurochemical and genetic factors in panic disorder: a systematic reviewMoraes ACN, et al. · Translational psychiatry · 2024PMID 39025836 ↗02Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-AnalysisBonvicini M, et al. · Nutrients · 2023PMID 36678257 ↗03The potential role of nutritional components in improving brain function among patients with Alzheimers disease: a meta-analysis of RCT studiesAlbrahim T · Neurosciences (Riyadh, Saudi Arabia) · 2020PMID 31982903 ↗04Application of Citicoline in Neurological Disorders: A Systematic ReviewJasielski P, et al. · Nutrients · 2020PMID 33053828 ↗05Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic reviewCanestaro WJ, et al. · Genetics in medicine : official journal of the American College of Medical Genetics · 2014PMID 24810685 ↗06Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pHWölke S, et al. · Molecular pharmaceutics · 2025PMID 41060706 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.